Lassa fever vaccine - Inovio Pharmaceuticals/United States Army Medical Research Institute of Infectious Diseases

Drug Profile

Lassa fever vaccine - Inovio Pharmaceuticals/United States Army Medical Research Institute of Infectious Diseases

Alternative Names: INO-4500

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Pharmaceuticals; United States Army Medical Research Institute of Infectious Diseases
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lassa fever

Most Recent Events

  • 11 Apr 2018 Inovio Pharmaceuticals signs partnership agreement with Coalition for Epidemic Preparedness Innovations (CEPI) for development of Lassa fever vaccine
  • 24 Oct 2017 Preclinical trials in Lassa fever (Prevention) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top